Jamie I Fletcher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8593636/publications.pdf Version: 2024-02-01



IAMIE I FLETCHED

#	Article	IF	CITATIONS
1	Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function. Molecular Cell, 2005, 17, 393-403.	9.7	1,639
2	Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes and Development, 2005, 19, 1294-1305.	5.9	1,071
3	Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak. Science, 2007, 315, 856-859.	12.6	1,021
4	ABC transporters in cancer: more than just drug efflux pumps. Nature Reviews Cancer, 2010, 10, 147-156.	28.4	920
5	Programmed Anuclear Cell Death Delimits Platelet Life Span. Cell, 2007, 128, 1173-1186.	28.9	910
6	ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resistance Updates, 2016, 26, 1-9.	14.4	316
7	The structure of a novel insecticidal neurotoxin, ω-atracotoxin-HV1, from the venom of an Australian funnel web spider. Nature Structural Biology, 1997, 4, 559-566.	9.7	172
8	Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18081-18087.	7.1	162
9	Calcium-dependent Plasma Membrane Binding and Cell Lysis by Perforin Are Mediated through Its C2 Domain. Journal of Biological Chemistry, 2005, 280, 8426-8434.	3.4	131
10	The structure of versutoxin (\hat{l} -atracotoxin-Hv1) provides insights into the binding of site 3 neurotoxins to the voltage-gated sodium channel. Structure, 1997, 5, 1525-1535.	3.3	115
11	ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux. Journal of the National Cancer Institute, 2011, 103, 1236-1251.	6.3	113
12	Structural Basis for Apoptosis Inhibition by Epstein-Barr Virus BHRF1. PLoS Pathogens, 2010, 6, e1001236.	4.7	99
13	Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma. Science Translational Medicine, 2019, 11, .	12.4	99
14	The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression. Oncotarget, 2016, 7, 8663-8675.	1.8	97
15	A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. Cancer Research, 2017, 77, 971-981.	0.9	90
16	Structure-function studies of omega-atracotoxin, a potent antagonist of insect voltage-gated calcium channels. FEBS Journal, 1999, 264, 488-494.	0.2	79
17	Too many targets, not enough patients: rethinking neuroblastoma clinical trials. Nature Reviews Cancer, 2018, 18, 389-400.	28.4	67
18	Functional Significance of the β-Hairpin in the Insecticidal Neurotoxin ω-Atracotoxin-Hv1a. Journal of Biological Chemistry, 2001, 276, 26568-26576.	3.4	66

Jamie I Fletcher

#	Article	IF	CITATIONS
19	Controlling the cell death mediators Bax and Bak: puzzles and conundrums. Cell Cycle, 2008, 7, 39-44.	2.6	58
20	Solution structure of a defensin-like peptide from platypus venom. Biochemical Journal, 1999, 341, 785-794.	3.7	57
21	High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4). Biochemical Pharmacology, 2014, 91, 97-108.	4.4	53
22	<i>MYC</i> -Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin. Cancer Research, 2016, 76, 3604-3617.	0.9	38
23	Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition. Drug Resistance Updates, 2021, 59, 100795.	14.4	38
24	The Structure of Ap4A Hydrolase Complexed with ATP-MgFx Reveals the Basis of Substrate Binding. Structure, 2002, 10, 205-213.	3.3	30
25	High-resolution solution structure of gurmarin, a sweet-taste-suppressing plant polypeptide. FEBS Journal, 1999, 264, 525-533.	0.2	29
26	MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells. Biochemical Pharmacology, 2019, 168, 237-248.	4.4	29
27	Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy. British Journal of Cancer, 2020, 122, 680-691.	6.4	28
28	Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against <i>MYCN</i> â€amplified neuroblastoma. International Journal of Cancer, 2020, 147, 1928-1938.	5.1	28
29	Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen. Biochemical Pharmacology, 2015, 93, 380-388.	4.4	27
30	Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan inAvivo. European Journal of Cancer, 2017, 83, 132-141.	2.8	24
31	Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface. Cancer Research, 2019, 79, 5652-5667.	0.9	24
32	Glutathione biosynthesis is upregulated at the initiation of MYCNâ€driven neuroblastoma tumorigenesis. Molecular Oncology, 2016, 10, 866-878.	4.6	23
33	Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition. Oncogene, 2020, 39, 3555-3570.	5.9	23
34	Targeted Therapy of <i>TERT</i> -Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy. Clinical Cancer Research, 2021, 27, 1438-1451.	7.0	20
35	The αM1 segment of the nicotinic acetylcholine receptor exhibits conformational flexibility in a membrane environment. Biochimica Et Biophysica Acta - Biomembranes, 2004, 1665, 40-47.	2.6	19
36	CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma. British Journal of Cancer, 2020, 123, 1101-1113.	6.4	17

JAMIE I FLETCHER

#	Article	IF	CITATIONS
37	Mouse models of high-risk neuroblastoma. Cancer and Metastasis Reviews, 2020, 39, 261-274.	5.9	17
38	Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC–Driven Cancer Progression. Cancer Research, 2020, 80, 3706-3718.	0.9	15
39	Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma. Clinical Cancer Research, 2021, 27, 4338-4352.	7.0	14
40	<i>MYCN</i> amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma. Oncotarget, 2015, 6, 15510-15523.	1.8	13
41	<i>In vitro</i> and <i>in vivo</i> drug screens of tumor cells identify novel therapies for highâ€risk child cancer. EMBO Molecular Medicine, 2022, 14, e14608.	6.9	12
42	N-Myc Regulates Expression of the Detoxifying Enzyme Glutathione Transferase <i>GSTP1</i> , a Marker of Poor Outcome in Neuroblastoma. Cancer Research, 2012, 72, 845-853.	0.9	11
43	Discovery of Inhibitors of Lupin Diadenosine 5′,5′′′aꀲa;i>P ¹ , <i>P</i> ⁴ -Tetraphosphate Hydrolase by Virtual Screening. Biochemistry, 2009, 48, 7614-7620.	2.5	7
44	Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma. British Journal of Cancer, 2022, 126, 482-491.	6.4	7
45	"We Have All This Knowledge to Give, So Use Us as a Resource†Partnering with Adolescent and Young Adult Cancer Survivors to Determine Consumer-Led Research Priorities. Journal of Adolescent and Young Adult Oncology, 2022, 11, 211-222.	1.3	6
46	GSH facilitates the binding and inhibitory activity of novel multidrug resistance protein 1 (MRP1) modulators. FEBS Journal, 2022, 289, 3854-3875.	4.7	6
47	Targeting Functional Activity of AKT Has Efficacy against Aggressive Neuroblastoma. ACS Pharmacology and Translational Science, 2020, 3, 148-160.	4.9	5
48	Methodological advances in the discovery of novel neuroblastoma therapeutics. Expert Opinion on Drug Discovery, 2021, , 1-13.	5.0	5
49	miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma. Molecular Therapy, 2022, 30, 1119-1134.	8.2	5
50	The Australian and New Zealand Children's Haematology/Oncology Group Biobanking Network. Biopreservation and Biobanking, 2019, 17, 95-97.	1.0	2
51	CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth. Biochemical Pharmacology, 2020, 172, 113770.	4.4	2
52	Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors. Cell Death and Disease, 2021, 12, 268.	6.3	2
53	Targeting Multidrug Resistance in Neuroblastoma. Pediatric Cancer, 2012, , 115-123.	0.0	1
54	A Primer for Assessing the Pathology in Mouse Models of Neuroblastoma. Current Protocols, 2021, 1, e310.	2.9	1

#	Article	IF	CITATIONS
55	Spider toxins: A new group of potassium channel modulators. Journal of Computer - Aided Molecular Design, 1999, 15/16, 61-69.	1.0	0
56	Letter to the Editor: 1H, 13C, and 15N resonance assignments of the 17 kDa Ap4A hydrolase from Homo sapiens in the presence and absence of ATP. Journal of Biomolecular NMR, 2005, 31, 181-182.	2.8	0